Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
Rhea-AI Summary
Senti Biosciences (Nasdaq: SNTI) will present on-stage at Healthcare Conference Taipei 2026 on Feb 10, 2026. The eight-minute session (10:30–10:40 AM local, Regent Ballroom, Track 1) will cover the Gene Circuit platform, pipeline progress, strategic priorities and partnership opportunities.
Management will host post-presentation networking at Table #1 in the Level 3 foyer.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SNTI declined 2.97%, reflecting a moderate negative market reaction. This price movement removed approximately $708K from the company's valuation, bringing the market cap to $23M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SNTI was up 1% while peers were mixed: MRSN +0.62%, LSB -20.62%, LVTX -3.87%, IPSC -2.65%, and MURA 0%, indicating stock-specific movement rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Investor presentation | Positive | +3.8% | CEO discussed new SENTI-202 data and recent RMAT and Orphan Drug designations. |
| Jan 09 | Conference panel | Positive | +2.8% | CEO joined Biotech Showcase panel on advances in cell and gene therapies. |
| Dec 18 | Inducement grant | Neutral | +2.6% | Board granted stock options to a new employee under the inducement equity plan. |
| Dec 09 | Regulatory designation | Positive | -35.6% | FDA granted RMAT designation to SENTI-202 for relapsed/refractory AML. |
| Dec 09 | Clinical data update | Positive | -35.6% | Updated SENTI-202 Phase 1 data showed durable remissions and favorable safety. |
Recent news has often been positive (regulatory, clinical, visibility events). Modest gains followed conference/investor communications, while strong clinical and RMAT updates in December saw sharp negative price reactions, indicating occasional divergence between positive fundamentals and near-term trading.
Over the last several months, Senti Biosciences has highlighted a series of regulatory, clinical, and visibility milestones. In Dec 2025, SENTI‑202 Phase 1 data and an FDA RMAT designation were announced, yet the stock fell about 35.56% on those updates, showing a sharp divergence from the positive clinical narrative. Subsequent items, including new inducement grants on Dec 12, 2025 and conference or investor participation on Jan 9 and Jan 14, 2026, saw modest positive reactions. Today’s conference presentation fits into this pattern of ongoing outreach and platform visibility.
Market Pulse Summary
This announcement centers on Senti Biosciences’ on‑stage presentation at Healthcare Conference Taipei 2026, highlighting its Gene Circuit platform, pipeline progress, and partnership priorities during an 8‑minute session on February 10, 2026. Historically, similar conference and investor engagements in January 2026 coincided with modest positive moves, while major clinical and regulatory milestones in December 2025 saw sharp downside. Investors may watch for follow‑on collaborations, financing developments, and further SENTI‑202 data as key future catalysts.
Key Terms
gene circuit medical
cell and gene therapies medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, has been selected to deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei happening February 10–11, 2026, at the Regent Taipei Hotel.
Senti’s presentation will be held on Tuesday, February 10, 2026, from 10:30 AM to 10:40 AM local time, in Track 1 at the Regent Ballroom (Level 3). The eight-minute presentation will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration.
“We are pleased to be selected for an on-stage presentation at Healthcare Conference Taipei 2026,” said Dr. Timothy Lu, Co-Founder and Chief Executive Officer of Senti. “This conference brings together a highly relevant group of global investors and strategic partners. We look forward to sharing how our Gene Circuit platform enables greater precision, control and safety in cell and gene therapies, as well as discussing potential collaborations to advance transformative therapeutic programs for patients.”
Following the presentation session for those invited and registered to attend the conference, management will be available for post-presentation networking during the scheduled conference break at Table #1 in the Level 3 foyer outside the Regent Ballroom.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
When and where will Senti Biosciences (SNTI) present at Healthcare Conference Taipei 2026?
What topics will Senti Biosciences (SNTI) cover during the Feb 10 presentation?
Who is presenting for Senti Biosciences (SNTI) at Healthcare Conference Taipei 2026?
Can investors meet Senti Biosciences (SNTI) management after the presentation on Feb 10?
